Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07044557 · ClinicalTrials.gov registry record · NA

MeDex: No Perioperative Dexamethasone in Brain Metastases

A NA study of Brain Metastases, sponsored by University of Louisville.

Recruiting
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT07044557 is a NA study of Brain Metastases that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 35 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07044557, a NA study of Brain Metastases, is actively recruiting participants, sponsored by University of Louisville.

RECRUITING
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

Conditions Studied

Interventions

  • OTHER Withholding perioperative Dexamethasone

Study Locations (1)

Kentucky

  • University of Louisville Hospital - Louisville

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2025-12-03
Est. Completion 2027-10
Phase NA

Sponsor

University of Louisville

217 total trials

What the Registry Record Tells You About NCT07044557

The ClinicalTrials.gov registry entry for NCT07044557 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (83% lower). The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Withholding perioperative Dexamethasone is the first listed.

NCT07044557 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT07044557 about?

NCT07044557 is a clinical study titled "MeDex: No Perioperative Dexamethasone in Brain Metastases". Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

What is the current status of trial NCT07044557?

This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2025-12-03. Estimated completion is 2027-10.

What conditions does trial NCT07044557 study?

This clinical trial studies the following conditions: Brain Metastases.

What interventions are being tested in trial NCT07044557?

The interventions under investigation include: Withholding perioperative Dexamethasone (OTHER).

Who is sponsoring clinical trial NCT07044557?

This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07044557 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Metastases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.